239 related articles for article (PubMed ID: 27353271)
1. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Lawitz EJ; Dvory-Sobol H; Doehle BP; Worth AS; McNally J; Brainard DM; Link JO; Miller MD; Mo H
Antimicrob Agents Chemother; 2016 Sep; 60(9):5368-78. PubMed ID: 27353271
[TBL] [Abstract][Full Text] [Related]
2. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
[TBL] [Abstract][Full Text] [Related]
3. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
4. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
[TBL] [Abstract][Full Text] [Related]
5. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
[TBL] [Abstract][Full Text] [Related]
6. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.
Camus G; Han B; Asselah T; Hsieh D; Dvory-Sobol H; Lu J; Svarovskaia E; Martin R; Parhy B; Miller MD; Brainard DM; Kersey K; Abergel A; Mo H
J Viral Hepat; 2018 Feb; 25(2):134-143. PubMed ID: 28984067
[TBL] [Abstract][Full Text] [Related]
7. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H
J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123
[TBL] [Abstract][Full Text] [Related]
8. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
[TBL] [Abstract][Full Text] [Related]
10. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
[No Abstract] [Full Text] [Related]
12. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Lawitz E; Freilich B; Link J; German P; Mo H; Han L; Brainard DM; McNally J; Marbury T; Rodriguez-Torres M
J Viral Hepat; 2015 Dec; 22(12):1011-9. PubMed ID: 26183611
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.
Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Wong KA; Jones CT; Jiang L; Lin K; Or YS
Antimicrob Agents Chemother; 2016 Oct; 60(10):6216-26. PubMed ID: 27503644
[TBL] [Abstract][Full Text] [Related]
14. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.
Liu Z; Mao X; Wu J; Yu K; Yang Q; Suo C; Lu M; Jin L; Zhang T; Chen X
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1906-1914.e25. PubMed ID: 31683059
[TBL] [Abstract][Full Text] [Related]
15. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
[TBL] [Abstract][Full Text] [Related]
16. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.
Wyles D; Mangia A; Cheng W; Shafran S; Schwabe C; Ouyang W; Hedskog C; McNally J; Brainard DM; Doehle BP; Svarovskaia E; Miller MD; Mo H; Dvory-Sobol H
Antivir Ther; 2018; 23(3):229-238. PubMed ID: 28650844
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
Vince B; Hill JM; Lawitz EJ; O'Riordan W; Webster LR; Gruener DM; Mofsen RS; Murillo A; Donovan E; Chen J; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Zhou XJ
J Hepatol; 2014 May; 60(5):920-7. PubMed ID: 24434503
[TBL] [Abstract][Full Text] [Related]
19. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
